Semi-classical dynamical triangulations

For non-critical string theory the partition function reduces to an integral over moduli space after integrating over matter fields. The moduli integrand is known analytically for genus one surfaces. The formalism of dynamical triangulations provides us with a regularization of non-critical string theory and we show that even for very small triangulations it reproduces very well the continuum integrand when the central charge c   of the matter fields is large negative, thus providing a striking example of how the quantum fluctuations of geometry disappear when c→−∞$c\to -\infty$.     

双功能催化剂催化CO2加氢制低碳烯烃反应中In2O3的尺寸效应

CO2催化加氢转化成高附加值化学品如低碳烯烃(C2=–C4=)等是减少碳排放的有效途径之一.采用金属氧化物/分子筛双功能催化剂可以实现CO2加氢直接高选择性合成C2+碳氢化合物.通常认为,金属氧化物组分可以活化CO2转化为甲醇等含氧中间体,该中间体在分子筛孔道内进一步转化为各种烃.氧化铟(In2O3)/SAPO-34双功能催化剂由于具有出色的催化CO2加氢制低碳烯烃反应性能而备受关注,然而,仍需进一步提升催化剂的催化性能以推动该反应的工业应用.目前,氧化物的结构与双功能催化剂性能之间的关系还不明确,这不利于其催化性能的改善.现有关于金属氧化物纳米粒子的尺寸(特别是小于23 nm)效应及其对双功能催化CO2加氢反应的活性和产物分布的影响的报道较少,对此深入理解将有利于设计更高性能的催化剂.本文采用沉淀法,通过控制焙烧温度得到了一系列尺寸为7～28 nm的立方相In2O3,通过多种表征手段探究了In2O3的尺寸对其结构与表面化学性质的影响.结果表明,随着In2O3晶粒尺寸的减小,其氧空位数目、CO2、H2与NH3吸附量以及Lewis较强酸性位比例均逐渐增加.在350oC,3 Mpa,9000 mL·gcat–1·h–1和H2/CO2比为3的反应条件下,研究了In2O3/SAPO-34双功能催化剂中In2O3粒径对其催化CO2加氢制低碳烯烃反应性能的影响.结果表明,随着双功能催化剂中In2O3尺寸的增大,低碳烯烃(尤其是丙烯)选择性、收率及烯烃与烷烃比例均先升高后降低,在尺寸为19 nm的In2O3上达到最大值,分别为76.9％、12.3 mmol goxide–1 h–1和4.8.较小尺寸的In2O3虽然具有较大的比表面积和更多的氧空位,并为CO2和H2的活化提供了更多的活性位,但小于19 nm的颗粒更容易烧结;In2O3的尺寸还会影响其与SAPO-34的协同效应,进而影响双功能催化剂的催化活性.此外,相对于其它尺寸的In2O3,19 nm的In2O3更有利于甲醇中间体的生成.因而19 nm In2O3耦合SAPO-34的双功能催化剂性能最好,其催化CO2转化率最高,为14.1％.综上,适中尺寸的In2O3能够促进In2O3/SAPO-34上CO2加氢制低碳烯烃反应.这些结果为通过平衡结构稳定性和催化性能来设计更有效的催化CO2转化的复合催化剂提供了理论指导.     

Bioanalytical method validation,biopharmaceutical and pharmacokinetic evaluation of GSK-650394, a serum- and glucocorticoid-regulated kinase 1 inhibitor

GSK-650394 is an inhibitor of serum- and glucocorticoid-regulated kinase 1 that displays potency for treating cancer, hypertension, cardiovascular and neuronal diseases, such as Parkinson’s disease. However, the biopharmaceutical properties and pharmacokinetics of GSK-650394 have not been studied extensively. Also, there are currently no bioanalytical assays available for this new drug candidate. In this study, we developed a simple and sensitive liquid chromatography-tandem mass spectrometry method to quantify GSK-650394 in rat plasma and validated its selectivity, linearity, accuracy and precision, sensitivity, matrix effects, extraction recovery, and stability, following the United States Food and Drug Administration guidelines. In vitro studies showed the biopharmaceutical properties of GSK-650394, including its low solubility in water and simulated gastrointestinal fluids, passive transport in Caco-2 cell monolayers, high plasma protein binding, and primary metabolism by glucuronide conjugation in the small intestine and liver of rats. Following intravenous administration (2 mg/kg) to rats, GSK-650394 exhibited low total clearance (11.18 ± 1.28 mL/min/kg) and volume of distribution at steady-state (346.1 ± 120.6 mL/kg). Following oral administration (2, 5, and 10 mg/kg) to rats, GSK-650394 underwent enterohepatic circulation, with low bioavailability (～9%). The insignificant difference in bioavailability among three oral doses suggests that GSK-650394 may follow linear pharmacokinetics up to an oral dose of 10 mg/kg. In addition, the total form of parent drug and glucuronide conjugate in rat plasma from three oral doses showed a much higher value of area under the plasma concentration versus time curve than the parent drug, indicating that the primary metabolism process of GSK-650394 was glucuronidation. Our findings suggest that the low oral bioavailability of GSK-650394 is associated with its low solubility, instability under acidic gastric conditions, and extensive glucuronidation metabolism.